RecruitingNot ApplicableNCT07322653

The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population

Prospective, Open-Label, Multicenter Study to Characterise the Effects of Co-administration of MediDrink Platinum+ Formula Containing Novel Protein Blend SPR-01 and Fava Bean Protein Hydrolysate on Fitness in an Aged Population


Sponsor

Nuritas Ltd

Enrollment

75 participants

Start Date

Sep 10, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Examining the effects of MediDrink Platinum+ containing novel protein blend SRP-01 alone or when combined with PeptiStrong on clinical responses in elderly adults with sarcopenia


Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying MediDrink Platinum+ and MediDrink Platinum+ and PeptiStrong for people with malnourished, muscle mass, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 60 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMediDrink Platinum+

MediDrink Platinum+ containing novel protein blend SPR-01

OTHERMediDrink Platinum+ and PeptiStrong

MediDrink Platinum+ containing novel protein blend SPR-01 and PeptiStrong, fava bean protein hydrolysate


Locations(2)

Országos Korányi Pulmonológiai Intézet

Budapest, Hungary

Sóstói Szivárvány Idősek Otthona

Nyíregyháza, Hungary

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07322653


Related Trials